Latest News
-
Unlocking the Mind’s Eye: How Huntington’s Disease Changes How We See and Process the World
For many with Huntington’s disease, recognising faces, navigating familiar places, or reading can be difficult. Scientists studied how and when HD affects how the brain processes what we see—crucial research to improve support for people with HD.
-
Precision huntingtin-lowering drug trials target the mutant protein
WAVE Life Sciences launches PRECISION clinical trial to suppress the mutant Huntington's disease protein
-
A step forward for gene editing: CRISPR-Cas9 and HD
Evolving CRISPR-Cas9 techniques can now be used to edit the HD gene in a living mouse brain.
-
Update confirms Huntington's disease 'gene silencing' trial on track
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
-
New study reveals a potential HD biomarker
A potential HD biomarker has been uncovered in a recent clinical study
-
Huntington's Disease Therapeutics Conference 2017 – Day 3
HDBuzz summarises final day of the 2017 Huntington's Disease Therapeutics Conference in Malta
-
Huntington's Disease Therapeutics Conference 2017 – Day 2
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 2
-
Huntington's Disease Therapeutics Conference 2017 – Day 1
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 1
-
Enemy at the gates – huntingtin disrupts nuclear transport
Two recent studies show how a cellular border control system goes wrong in HD, opening new avenues for HD research.
-
FDA approves a new drug for symptoms of Huntington's disease
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease